Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M

Keros Therapeutics, Inc.

Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.
Cash and equivalents $287.4M as of Dec 31, 2025, expected to fund operations into first half of 2028.
R&D expenses fell to $17.9M (Q4) and $129.6M (FY) due to transition of elritercept costs to Takeda.
Charles Newton appointed to board effective March 9, 2026; Carl Gordon steps down. Esther Cho promoted to Chief Legal Officer.
Phase 2 trial of rinvatercept for DMD expected to start in Q2 2026; ALS regulator engagement planned for H2 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Keros Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income net loss of $23.5 million.

Period: the fourth quarter ended December 31, 2025
Net income: net loss of $23.5 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $23.5 million for the fourth quarter

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Keros Therapeutics, Inc. reported the year ended December 31, 2025 results: net income net income of $87.0 million.

Period: the year ended December 31, 2025
Net income: net income of $87.0 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $23.5 million for the fourth quarter and net income of $87.0 million for the year ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-26-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.